Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; povidone; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25) - drospirenone 3 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - drospirenone ; ethinyl estradiol - film coated tablet - 0.02/3.0 milligram - drospirenone and ethinylestradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios leon farma, s.a. - drospirenone ethinylestradiol - film coated tablet - 0.02 / 3 milligram

United States - English - NLM (National Library of Medicine)

medvantx, inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - gianvi is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. oral contraceptives are highly effective. table ii lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization and contraceptive implants and iuds, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. gianvi is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who choose to use an oral contraceptive as their method of contraception. the effectiveness of gianvi for pmdd when used for more than three menstrual cycles has not been evaluated. the essential features of pmdd according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. other featur

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - ethinylestradiol/ drospirenone tablet is indicated for use as:,?an oral contraceptive.,?treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of ethinylestradiol/ drospirenone tablet for pmdd was not assessed beyond 3 cycles. ethinylestradiol/ drospirenone tablet has not been evaluated for treatment of pms (premenstrual syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.